You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藍帆醫療(002382.SZ):截至到一季度,心腦血管事業部研發費用超過4700萬元
格隆匯 06-13 07:55

格隆匯6月13日丨藍帆醫療(002382.SZ)接受機構調研,互動交流環節中,就“請問2022年的研發費用是多少?2023年是否會加大研發投入?具體投入哪些項目?”

公司回覆稱,公司2022年度研發投入近4億元,研發費用約3.5億元。2023年研發費用將根據公司未來發展、項目進展情況進行投入,截至到2023年一季度,心腦血管事業部研發費用超過4,700萬元,涉及BA9冠脈藥物球囊(新增支架內再狹窄適應症)、冠脈IVL球囊、冠脈CTO球囊、冠脈刻痕球囊、乳突防滑球囊、主動脈瓣膜、瓣膜IVL球囊、二尖瓣修復、三尖瓣修復、定向斑塊旋切系統、鋸齒切割球囊、灌注球囊和高分子瓣膜等多個重磅在研產品。

未來,公司將統籌整合各事業部的研發資源,不斷根據公司的業務戰略佈局、技術趨勢和客户需求研製開發新技術、新產品,同時將研發成果產業化,持續將科技創新能力作為企業發展的核心競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account